BMY’s admilparant hits IPF trial goal, but only at lower doseBy Martin Holloway13/10/2026 Bristol Myers Squibb’s admilparant Phase 3 trial met its primary endpoint in IPF, but only the 60mg dose reached significance, filings show.
